Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

VJVirtual | CD19 CAR-T in lymphoma patients in the UK

Andrea Kuhnl • 23 May 2020
Lymphoma

Andrea Kuhnl, MD, of King’s College Hospital NHS Foundation Trust, London, UK, discusses real-world data of high-grade lymphoma patients treated with CD19 CAR-T in the UK. These data were submitted as an abstract to the BSH 2020 meeting. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Andrea Kuhnl

Widespread adoption of CAR-T therapy in the UK: fostering specialist networks 1:02
Widespread adoption of CAR-T therapy in the UK: fostering specialist networks
Andrea Kuhnl • 18 Jun 2025
The use of early PET responses to predict the risk of relapse after second-line axi-cel in LBCL 1:14
The use of early PET responses to predict the risk of relapse after second-line axi-cel in LBCL
Andrea Kuhnl • 18 Jun 2025
The efficacy and feasibility of using radiotherapy as a bridge to CAR-T in patients with lymphoma 1:27
The efficacy and feasibility of using radiotherapy as a bridge to CAR-T in patients with lymphoma
Andrea Kuhnl • 18 Jun 2025
Experience with the RESTART protocol: integrating radiotherapy into the peri-CAR-T setting for LBCL 1:33
Experience with the RESTART protocol: integrating radiotherapy into the peri-CAR-T setting for LBCL
Andrea Kuhnl • 18 Jun 2025

Related Videos

Long-term follow-up results from ELM-2: odronextamab in R/R FL 8:08
Long-term follow-up results from ELM-2: odronextamab in R/R FL
Gottfried von Keudell • 18 Sep 2025
The efficacy of glofitamab in patients with heavily pre-treated R/R MCL 1:24
The efficacy of glofitamab in patients with heavily pre-treated R/R MCL
Tycel Phillips • 5 Sep 2025
Bringing clinical trials to the community: current approaches at Sarah Cannon Research Institute 1:01
Bringing clinical trials to the community: current approaches at Sarah Cannon Research Institute
Krish Patel • 4 Sep 2025
Bispecifics and CAR T-cell therapy in lymphoma: sequencing strategies and considerations 1:52
Bispecifics and CAR T-cell therapy in lymphoma: sequencing strategies and considerations
Tycel Phillips • 5 Sep 2025
The content of VJHemOnc is intended for healthcare professionals